The International Society of Hair Restoration Surgery (ISHRS) awarded four grants to leading clinical investigators worldwide during its 24th World Congress in October 2016.
The recipients included:
Paul V. Shapiro, MD, of Minneapolis for “Use of Finasteride and the Onset of Depression: A Prospective Cohort Study.” The drug finasteride, sold under the brand name Propecia, is a widely used oral medication prescribed for male pattern hair loss (androgenic alopecia.) While effective, the drug may cause some side effects in a subset of men. In this study, Dr. Shapiro hypothesizes that patients with a predisposition to depression who take finasteride are more likely to develop depression than those without any predisposition. The goal is to help surgeons define better candidates for the therapy and minimize the risk of side effects among subsets of patients. Co-researchers include David S. Josephitis, DO, FISHRS, and Mark Schuler, PhD, both of Minneapolis.
Gregory Williams, MBBS, FISHRS, faculty member at University College London and Claire Higgins, PhD, lecturer, Department of Bioengineering at Imperial College London, England for “Bisulfite Sequencing of Human...